[HTML][HTML] First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial …
M Schuler, EH Tan, K O'Byrne, L Zhang… - Journal of cancer …, 2019 - Springer
Purpose In the randomized phase IIb LUX-Lung 7 trial, afatinib significantly improved
progression-free survival (PFS) and time-to-treatment failure vs gefitinib in patients with …
progression-free survival (PFS) and time-to-treatment failure vs gefitinib in patients with …
[HTML][HTML] First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial …
M Schuler, EH Tan, K O'Byrne, L Zhang… - Journal of Cancer …, 2019 - ncbi.nlm.nih.gov
Purpose In the randomized phase IIb LUX-Lung 7 trial, afatinib significantly improved
progression-free survival (PFS) and time-to-treatment failure vs gefitinib in patients with …
progression-free survival (PFS) and time-to-treatment failure vs gefitinib in patients with …
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial …
M Schuler, EH Tan, K O'Byrne, L Zhang… - Journal of Cancer …, 2019 - europepmc.org
Purpose In the randomized phase IIb LUX-Lung 7 trial, afatinib significantly improved
progression-free survival (PFS) and time-to-treatment failure vs gefitinib in patients with …
progression-free survival (PFS) and time-to-treatment failure vs gefitinib in patients with …
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial …
M Schuler, EH Tan, K O'Byrne… - Journal of Cancer …, 2019 - search.ebscohost.com
Purpose: In the randomized phase IIb LUX-Lung 7 trial, afatinib significantly improved
progression-free survival (PFS) and time-to-treatment failure vs gefitinib in patients with …
progression-free survival (PFS) and time-to-treatment failure vs gefitinib in patients with …
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial …
M Schuler, EH Tan, K O'Byrne… - Journal of cancer …, 2019 - pubmed.ncbi.nlm.nih.gov
Purpose In the randomized phase IIb LUX-Lung 7 trial, afatinib significantly improved
progression-free survival (PFS) and time-to-treatment failure vs gefitinib in patients with …
progression-free survival (PFS) and time-to-treatment failure vs gefitinib in patients with …
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial …
M Schuler, EH Tan, K O'Byrne, L Zhang… - JOURNAL OF …, 2019 - scholarworks.bwise.kr
PurposeIn the randomized phase IIb LUX-Lung 7 trial, afatinib significantly improved
progression-free survival (PFS) and time-to-treatment failure vs gefitinib in patients with …
progression-free survival (PFS) and time-to-treatment failure vs gefitinib in patients with …
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial …
M Schuler, EH Tan, K O'Byrne… - Journal of cancer …, 2019 - mdanderson.elsevierpure.com
Purpose: In the randomized phase IIb LUX-Lung 7 trial, afatinib significantly improved
progression-free survival (PFS) and time-to-treatment failure vs gefitinib in patients with …
progression-free survival (PFS) and time-to-treatment failure vs gefitinib in patients with …
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial …
M Schuler, EH Tan, K O'Byrne, L Zhang… - Journal of Cancer …, 2019 - eprints.qut.edu.au
Purpose: In the randomized phase IIb LUX-Lung 7 trial, afatinib significantly improved
progression-free survival (PFS) and time-to-treatment failure vs gefitinib in patients with …
progression-free survival (PFS) and time-to-treatment failure vs gefitinib in patients with …
[PDF][PDF] First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial …
M Schuler - d-nb.info
Purpose In the randomized phase IIb LUX-Lung 7 trial, afatinib significantly improved
progression-free survival (PFS) and time-to-treatment failure vs gefitinib in patients with …
progression-free survival (PFS) and time-to-treatment failure vs gefitinib in patients with …
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial …
M Schuler, EH Tan, K O'Byrne, L Zhang… - Journal of Cancer …, 2019 - inis.iaea.org
Purpose In the randomized phase IIb LUX-Lung 7 trial, afatinib significantly improved
progression-free survival (PFS) and time-to-treatment failure vs gefitinib in patients with …
progression-free survival (PFS) and time-to-treatment failure vs gefitinib in patients with …